A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations

NCT01342965 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

217

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Erlotinib
DRUG: Chemotherapy

Sponsor

Hoffmann-La Roche